Kibur Medical
Kibur Medical is a privately held company based in Boston that transforms cancer care by accelerating oncology drug development and precision medicine. Their key product, the NanoNail™, is an innovative tumor-implanted, drug-eluting microdevice that simultaneously profiles tumor response to up to 20 different oncology drugs or drug combinations in vivo. This technology provides comprehensive multi-omic, spatially registered, single-cell data analyzed with advanced machine learning and bioinformatics, enabling drug developers to design more potent, better tolerated therapies with increased clinical success chances. The solution reduces clinical attrition, development risk, and costs by providing early insights into drug efficacy and mechanisms of action, validated through extensive scientific and clinical studies including seven FDA-approved clinical trials. Kibur Medical's technology also supports identifying predictive biomarkers and optimal drug combinations, positioning the company as a leader in precision oncology drug and diagnostic development.
Kibur Medical
Kibur Medical is a privately held company based in Boston that transforms cancer care by accelerating oncology drug development and precision medicine. Their key product, the NanoNail™, is an innovative tumor-implanted, drug-eluting microdevice that simultaneously profiles tumor response to up to 20 different oncology drugs or drug combinations in vivo. This technology provides comprehensive multi-omic, spatially registered, single-cell data analyzed with advanced machine learning and bioinformatics, enabling drug developers to design more potent, better tolerated therapies with increased clinical success chances. The solution reduces clinical attrition, development risk, and costs by providing early insights into drug efficacy and mechanisms of action, validated through extensive scientific and clinical studies including seven FDA-approved clinical trials. Kibur Medical's technology also supports identifying predictive biomarkers and optimal drug combinations, positioning the company as a leader in precision oncology drug and diagnostic development.